Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
AesRx reports promising data for sickle cell disease drug
AesRx said data from a Phase I study of its sickle cell disease treatment Aes-103 showed the drug is safe and well-tolerated by patients. The data are set to be presented at a hematology meeting. Following the positive findings, AesRx has started a second trial at the NIH Clinical Center in Bethesda, Md., that will involve patients with sickle cell disease.
Or we can send an email on your behalf